|
|
|
||
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
The
|
||
|
|
The
|
Explanatory Note
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(a)
|
Financial statements of businesses or funds acquired.
|
(b)
|
Pro forma financial information.
|
CYCLO THERAPEUTICS, INC.
|
||
Date: March 4, 2024
|
By:
|
/s/ N. Scott Fine
|
N. Scott Fine, Chief Executive Officer
|
-8?20$3;8T.P6BP^0"X99K>]9!:G
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end